BALAXI23.09

BALAXI PHARMACEUTICALS LIMITED

· Unclassified
₹ CrorePeersPARSTEELCITYLATTEYSCROWNHECPROJECTHINDCONAIROLAMGROBTEAMcap ₹127 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity-1.1910.820.570.57
Return on Assets-0.928.080.420.42
Return on Capital Employed21.8613.812.152.15
Return on Invested Capital11.3912.660.880.90
Margins
EBITDA Margin19.3712.723.163.23
Operating Margin18.5012.072.362.36
Incremental Operating Margin-18.16129.29
Pretax Margin0.849.801.962.31
Net Income Margin-0.998.570.520.87
FCF Margin1.73-12.43-7.16-7.16
Additional
Effective Tax Rate218.4412.5573.2362.58
Sustainable Growth Rate-1.1910.820.570.57
Incremental Operating Margin %-18.16129.291.29
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.